Related references
Note: Only part of the references are listed.The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy
Bethany Doran et al.
JACC-HEART FAILURE (2021)
Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review
Sergio Barra et al.
EUROPEAN HEART JOURNAL (2020)
Time trends in sudden cardiac death risk in heart failure patients with cardiac resynchronization therapy: a systematic review
Sergio Barra et al.
EUROPEAN HEART JOURNAL (2020)
Impact of mineralocorticoid receptor antagonists on the risk of sudden cardiac death in patients with heart failure and left-ventricular systolic dysfunction: an individual patient-level meta-analysis of three randomized-controlled trials
Xavier Rossello et al.
CLINICAL RESEARCH IN CARDIOLOGY (2019)
Very long-term survival and late sudden cardiac death in cardiac resynchronization therapy patients
Sergio Barra et al.
EUROPEAN HEART JOURNAL (2019)
Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014
Samir Saba et al.
HEART RHYTHM (2019)
Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018)
Thomas Olsen et al.
EUROPEAN HEART JOURNAL (2019)
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier
Simon van der Pol et al.
VALUE IN HEALTH (2019)
Sex-Specific Differences in Survival and Heart Failure Hospitalization After Cardiac Resynchronization Therapy With or Without Defibrillation
Francisco Leyva et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Survival after cardiac resynchronization therapy: results from 50 084 implantations
Francisco Leyva et al.
EUROPACE (2019)
Importance of beta-blocker dose in prevention of ventricular tachyarrhythmias, heart failure hospitalizations, and death in primary prevention implantable cardioverter-defibrillator recipients: a Danish nationwide cohort study
A. C. Ruwald et al.
EUROPACE (2018)
Device complications with addition of defibrillation to cardiac resynchronisation therapy for primary prevention
Sergio Barra et al.
HEART (2018)
Cardiac resynchronization therapy in the ageing population - With or without an implantable defibrillator?
Michael Doering et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2018)
Sacubitril/Valsartan (LCZ696): A Novel Treatment for Heart Failure and its Estimated Cost Effectiveness, Budget Impact, and Disease Burden Reduction in Germany
Afschin Gandjour et al.
PHARMACOECONOMICS (2018)
Morbidity and mortality with cardiac resynchronization therapy with pacing vs. with defibrillation in octogenarian patients in a real-world setting
Avishag Laish-Farkash et al.
EUROPACE (2017)
Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial
Claire Williams et al.
MEDICAL DECISION MAKING (2017)
Devices for management of sudden cardiac death: Successes, challenges and perspectives
Nikolaos Dagres et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Adding Defibrillation Therapy to Cardiac Resynchronization on the Basis of the Myocardial Substrate
Sergio Barra et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Declining Risk of Sudden Death in Heart Failure
Li Shen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Applicability of a risk score for prediction of the long-term benefit of the implantable cardioverter defibrillator in patients receiving cardiac resynchronization therapy
Sergio Barra et al.
EUROPACE (2016)
A review of economic evaluation models for cardiac resynchronization therapy with implantable cardioverter defibrillators in patients with heart failure
F. Tomini et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2016)
Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients
Akshay S. Desai et al.
EUROPEAN HEART JOURNAL (2015)
Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation
Jill L. Colquitt et al.
HEALTH TECHNOLOGY ASSESSMENT (2014)
Cost-effectiveness of long-acting injectable risperidone versus flupentixol decanoate in the treatment of schizophrenia: a Markov model parameterized using administrative data
Simon Frey et al.
EUROPEAN JOURNAL OF HEALTH ECONOMICS (2014)
Cost-effectiveness of cardiac resynchronization therapy in patients with heart failure: The perspective of a middle-income country's public health system
Eduardo G. Bertoldi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2013)
Survival Analysis for Economic Evaluations Alongside Clinical Trials-Extrapolation with Patient-Level Data: Inconsistencies, Limitations, and a Practical Guide
Nicholas R. Latimer
MEDICAL DECISION MAKING (2013)
Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
Andrew H. Briggs et al.
VALUE IN HEALTH (2012)
State-Transition Modeling: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-3
Uwe Siebert et al.
VALUE IN HEALTH (2012)
The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: A systematic review
Gina Magyar-Russell et al.
JOURNAL OF PSYCHOSOMATIC RESEARCH (2011)
Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure A Systematic Review
Alexander Goehler et al.
PHARMACOECONOMICS (2011)
Cost-effectiveness of cardiac resynchronisation therapy for patients with moderate-to-severe heart failure: a lifetime Markov model
Mattias Neyt et al.
BMJ OPEN (2011)
The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator
Guiqing Yao et al.
EUROPEAN HEART JOURNAL (2007)
Longer-term effects of cardiac resynchronization therapy on mortality in heart failure [the CArdiac REsynchronization-Heart Failure (CARE-HF) trial extension phase]
John G. F. Cleland et al.
EUROPEAN HEART JOURNAL (2006)
Cost-effectiveness acceptability curves - facts, fallacies and frequently asked questions
E Fenwick et al.
HEALTH ECONOMICS (2004)
Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure
MR Bristow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
